FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Lentini Renee					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]				(Che	elationship o eck all applic Directo	able)	10	% Ow	ner		
(Last) (First) (Middle) 830 WINTER STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/05/2021				7	below)	-Fin., Prir	be	Other (specify below)			
(Street) WALTHA			02451 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable) Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date				Fransaction te onth/Day/Y	Execution Date,		Code (Inst	n Disposed	5) (A) or B		5. Amount Securities Beneficial Owned F Reported Transact	s ally ollowing I ion(s)	Form: Direction (D) or Indirection (I) (Instr. 4)		. Nature of ndirect seneficial bwnership nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, I Execution Date, I Gecurity or Exercise (Month/Day/Year)		Code (insaction of		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		es J Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Owner Form Director Ind (I) (In	(D) irect	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Common Stock (right to buy)	\$7.69	02/05/2021		A		80,800		02/05/2022 ⁽¹⁾	02/05/2031	Common Stock	80,800	\$7.69	80,800	I)	

Explanation of Responses:

1. These options vest over a four-year period, with 25% of the shares vesting on the one year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant.

/s/ Renee Lentini

02/09/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.